Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.
Study Type
OBSERVATIONAL
Enrollment
249
CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .
Klinik für Herzchirurgie, Universitätsspital Basel
Basel, Switzerland
In-Hospital mortality
In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption
Time frame: during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
time in intensive care unit (days)
time in intensive care unit (days)
Time frame: during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
In-Hospital time (days)
In-Hospital time (days)
Time frame: hospital stay for cardiac surgery from admission until discharge (approximately 15 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.